Mitra Debdeep, Chopra Ajay, Saraswat Neerja, Mitra Barnali, Talukdar Krishna, Agarwal Reetu
Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India.
Department of Pediatrics, Base Hospital Delhi Cantt, New Delhi, India.
Indian Dermatol Online J. 2020 May 10;11(3):319-327. doi: 10.4103/idoj.IDOJ_407_18. eCollection 2020 May-Jun.
Skin and subcutaneous diseases affect millions of people worldwide, causing significant morbidity. Biologics are becoming increasingly useful for the treatment of many skin diseases, particularly as alternatives for patients who have failed to tolerate or respond to conventional systemic therapies. Biological therapies provide a targeted approach to treatment through interaction with specific components of the underlying immune and inflammatory disease processes. Advances in the understanding of disease pathophysiology for inflammatory skin diseases and in drug development have ushered in biologic therapies in dermatology. Biologic therapies are molecules that target specific proteins implicated in immune-mediated disease. This review article highlights the increasing evidence base for biologics in dermatology for off-label use.
皮肤和皮下疾病影响着全球数百万人,导致严重的发病率。生物制剂在治疗许多皮肤疾病方面变得越来越有用,特别是作为那些无法耐受或对传统全身治疗无反应的患者的替代疗法。生物疗法通过与潜在免疫和炎症疾病过程的特定成分相互作用,提供了一种有针对性的治疗方法。对炎症性皮肤病疾病病理生理学的理解以及药物开发的进展,已在皮肤科引入了生物疗法。生物疗法是针对免疫介导疾病中特定蛋白质的分子。这篇综述文章强调了生物制剂在皮肤科用于标签外使用的证据基础日益增加。